# Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT07751289** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yanjie Zhang, MD** · enrollment: 217 (estimated)

## Conditions studied

- Recurrent Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Neoadjuvant PD-1 antibody plus chemotherapy
- **PROCEDURE:** surgery
- **DRUG:** Adjuvant PD-1 antibody

## Key facts

- **NCT ID:** NCT07751289
- **Lead sponsor:** Yanjie Zhang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 217 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07751289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07751289, "Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07751289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*